Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.

Molecular cancer therapeutics - 1 Sept 2004

Bacolod Manny D, Johnson Stewart P, Pegg Anthony E, Dolan M Eileen, Moschel Robert C, Bullock Nancy S, Fang Qingming, Colvin O Michael, Modrich Paul, Bigner Darell D, Friedman Henry S

Abstract excerpt

The chemotherapeutic activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) may be improved by the addition of O6-benzylguanine (O6-BG). The reaction of O6-BG with O6-alkylguanine-DNA alkyltransferase (AGT) prevents the repair of O6-chloroethyl lesions caused by BCNU. In clinics, the combination of O6-BG and BCNU is now being tested for the treatment of brain tumors. However, the effectiveness of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Deoxyguanosine

Share to Drug Resistance, Neoplasm

Share to Guanine

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 15367707

Genes

AGT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.PMID 15367707Read ↗

Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaSemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell LinesSemantic proximity Read ↗

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsSemantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read ↗

Recent Approaches to Improve the Antitumor Efficacy of TemozolomideSemantic proximity Read ↗

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational ApplicationsSemantic proximity Read ↗

Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.Semantic proximity Read ↗

Drug-resistance in central nervous system tumors: from the traditional cell-resistance model to the genetically driven approaches on therapy.Semantic proximity Read ↗

Mechanism-based design of agents that selectively target drug-resistant gliomaSemantic proximity Read ↗

Clinical Relevance of <i>MGMT</i> in the Treatment of CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.